MX2014005927A - Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2. - Google Patents

Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2.

Info

Publication number
MX2014005927A
MX2014005927A MX2014005927A MX2014005927A MX2014005927A MX 2014005927 A MX2014005927 A MX 2014005927A MX 2014005927 A MX2014005927 A MX 2014005927A MX 2014005927 A MX2014005927 A MX 2014005927A MX 2014005927 A MX2014005927 A MX 2014005927A
Authority
MX
Mexico
Prior art keywords
combination
phosphoinositide
pathway
kinase
activator
Prior art date
Application number
MX2014005927A
Other languages
English (en)
Inventor
Mohamed Bentires-Alj
Adrian Britschgi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014005927A publication Critical patent/MX2014005927A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una combinación farmacéutica que comprende: (a) un compuesto inhibidor de la fosfoinositida-3-cinas a y (b) un compuesto que modula la senda de JAK2-STAT5 para el tratamiento de una enfermedad proliferativa, especialmente una enfermedad de un tumor sólido; a una composición farmacéutica que comprende dicha combinación; al uso de dicha combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a un envase o producto comercial que comprende esta combinación como una preparación combinada para el uso simultáneo, separado o secuencial; y a un método para el tratamiento de un animal de sangre caliente, especialmente un ser humano.
MX2014005927A 2011-11-15 2012-11-14 Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2. MX2014005927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11189194 2011-11-15
PCT/EP2012/072657 WO2013072392A1 (en) 2011-11-15 2012-11-14 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway

Publications (1)

Publication Number Publication Date
MX2014005927A true MX2014005927A (es) 2014-06-05

Family

ID=47191744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005927A MX2014005927A (es) 2011-11-15 2012-11-14 Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2.

Country Status (12)

Country Link
US (1) US20140343128A1 (es)
EP (1) EP2780017A1 (es)
JP (1) JP2014533294A (es)
KR (1) KR20140091695A (es)
CN (1) CN103945850A (es)
AU (2) AU2012338869A1 (es)
BR (1) BR112014011645A2 (es)
CA (1) CA2855619A1 (es)
HK (1) HK1197020A1 (es)
MX (1) MX2014005927A (es)
RU (1) RU2014124184A (es)
WO (1) WO2013072392A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9790504B2 (en) 2013-05-24 2017-10-17 The University Of Chicago Anti-tumor therapy
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3074016A2 (en) * 2013-11-26 2016-10-05 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
WO2016033100A1 (en) 2014-08-25 2016-03-03 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
US11878047B2 (en) * 2018-01-03 2024-01-23 Sapience Therapeutics, Inc. ATF5 peptide variants and uses thereof
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
USRE37421E1 (en) 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
GB9315914D0 (en) 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
PT833828E (pt) 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
BR0211905A (pt) 2001-08-22 2004-09-21 Wyeth Corp Dialdeìdos de rapamicina
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
BRPI0413146A (pt) 2003-08-28 2006-10-03 Novartis Ag dúplex rna interferindo tendo extremidades-embotadas e modificações-3
WO2005059132A1 (en) 2003-12-10 2005-06-30 Novartis Ag Rnai potency prediction method
AU2005214352B2 (en) 2004-02-14 2009-11-12 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0514206A (pt) 2004-08-10 2008-06-03 Wyeth Corp composto, anticorpo, kit para monitorar a terapia com cci-779, e, métodos para detectar metabólitos de cci-779, e para produzir um metabólito sintético e um derivado de cci-779
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CN101981036B (zh) 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
PT2675451E (pt) * 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
CA2844507A1 (en) * 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy

Also Published As

Publication number Publication date
HK1197020A1 (en) 2015-01-02
RU2014124184A (ru) 2015-12-27
KR20140091695A (ko) 2014-07-22
CN103945850A (zh) 2014-07-23
CA2855619A1 (en) 2013-05-23
AU2016202503A1 (en) 2016-05-12
BR112014011645A2 (pt) 2017-05-02
US20140343128A1 (en) 2014-11-20
JP2014533294A (ja) 2014-12-11
AU2012338869A1 (en) 2014-06-05
EP2780017A1 (en) 2014-09-24
WO2013072392A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
MX2014005927A (es) Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2.
MX336723B (es) Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
PH12017500453A1 (en) Spirocyclic inhibitors of cathepsin c
WO2014097151A3 (en) Autotaxin inhibitors
MY161088A (en) Agonists of gpr40
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
PH12014501157A1 (en) Pharmaceutical formulations
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
MX2011012201A (es) Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.
MX2015016497A (es) Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX370175B (es) Formulaciones de compuestos orgánicos.
UA113975C2 (xx) Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти)
MX2013002649A (es) Agente terapeutico contra el dolor.
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases
MX362533B (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
TN2009000427A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers